Alive & kicking..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most buys over .0025. Gonna pop
FLoat is 126 Million as of last Friday, June 5
PNOW .0022, VFIN is OUT.... 126m float
PNOW very thin now, morning seller is out..
Float JUST 126 MILLION
Sellers and flippers out. Thinner to the upside now
Float 126m as of june 5
agree, all OTC are a risk, ride the MOMO and trade L2. Don't marry them.
Always feel bad for those who's lose money. we all lose $$ at some point. but peeps who cry all day are just making it worse for new buyers to make a profit as well.
Crying doesn't help anyone.
jmho
Most of yesterdays volume was above .001, pps was taken down in the afternoon on fairly low volume for a trip.
See how it goes today.
L2 is clean. Just Retail here.
BBDA .001, Shorts got caught, NITE trying to cover here, L2 real thin
Shorts got caught with their pants down, .0017 will be tested again
L2 is thin and ready to make $$$
BBDA, just look at L2, I think you'll want some, V is GONE
L2 is very thin, could be be a very strong close
BBDA News, Look at L2, very thin
L2 is clean. Lets roll
BBDA .0013 up on share retirement news
BBDA News, retired 43m shares
BBDA .001up, short squeeze, HOD .0017
L2 is clean now, just retail here, VNDM out
Break up 15,, let her run
MNZO Barchart Opinion 80% BUY
http://www.barchart.com/opinions/stocks/MNZO
MNZO - Stockcharts.com BULLISH across the board
Also noted as OVERSOLD REVERSAL. Could see more volume tomorrow from chart players.
http://www.stockta.com/cgi-bin/analysis.pl?cobrand=&price=.0005&price=.005&volume=5000000&volume=&country=&alert=30&action=Module&symb=MNZO
Look at these charts:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114412083
Do you have accurate number on the float?
.0018's taken out in a heartbeat, been no dumpage. Tomorrow .002's imo
MNZO Pharmaceutical, .0019 up, 18 just got hammered
MNZO .0018 Chart: Indicators looking good
News:
Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin
http://www.otcmarkets.com/stock/MNZO/news/Manzo-Pharmaceuticals-announces-exciting-new-product-release-as-the-company-prepares-for-the-full-scale-human-study-of-its-Lacto-Freedom-product-to-begin?id=106630&b=y
Authorized Shares 1,900,000,000 a/o Mar 31, 2015
Outstanding Shares 504,522,000 a/o Mar 31, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 374,243,760 a/o Mar 31, 2015
Barchart 80% Buy. Don't see that often anymore
all games in an attempt to collect shares under .002
Askhole on .002, you'd Make alot more $$ selling at .004
.002 fake wall. They don't want to lose their shares
.002 falls and we see .003 pretty quick imo
MNZO .002 up,, VERY VERY THIN... No DILUTION
MNZO Pharmaceutical NEWS: prepares for the full-scale human study
Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin
PR Newswire
MILFORD, Pa., June 8, 2015
MILFORD, Pa., June 8, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has finished the development of its newest product, a natural sleep aid that the company has named Somnaid™. This news comes at the same time that Manzo Pharmaceuticals acknowledges positive results on its preliminary human study, and is now preparing to begin its full-scale human study of the company's ground breaking lactose intolerance product, Lacto-Freedom™.
Somnaid™ will target a much larger demographic than the company's previously released natural supplement product for babies with colic, and offer consumers a natural sleep aid that is triple acting, and designed specifically to deliver the right amounts of its natural ingredients to the consumer. Somnaid™ has been in the works for quite some time and the company CEO, Mr. Kenneth Manzo feels confident that it is better than any other natural sleep aid on the market. "I drew upon my extensive knowledge and many years of experience as a licensed pharmacist to achieve the perfect formula for deep restful sleep," said Manzo. "I also wanted to focus on products that have a large target market like Lacto-Freedom does in order to create a line of products that is as profitable as it is effective." For more information visit www.somnaid.com
The other important development for Manzo Pharmaceuticals is the positive result from the preliminary study that was done recently using Lacto-Freedom™ on a small group of human subjects. After the success of the preliminary study, it has been decided that Celprogen will be conducting the full-scale human study, in place of the clinical research company previously chosen, which will allow Manzo pharmaceuticals to get the product on the fast track to public release. "We need to get Lacto-Freedom™ to the consumer as quickly as possible. Every test we have done has had nothing but tremendous results. We have tested, and tested, and tested again, so after the full scale controlled human study, Lacto-Freedom™ will be just about ready for public release, hopefully changing the lives of millions of people all over the world," added Manzo.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose intolerance, a natural remedy for colic in babies, and a natural sleep aid. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-exciting-new-product-release-as-the-company-prepares-for-the-full-scale-human-study-of-its-lacto-freedom-product-to-begin-300095221.html
SOURCE Manzo Pharmaceuticals, Inc.
Thursday.